Epithelial mesenchymal transition status is associated with anti-cancer responses towards receptor tyrosine-kinase inhibition by dovitinib in human bladder cancer cells

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Hänze, Jörg ^a   Henrici, Marcus ^a   Hegele, Axel ^a   Hofmann, Rainer ^a   Olbert, Peter J ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Bladder cancer; Epithelial mesenchymal transition; Receptor tyrosine kinase; Tyrosine kinase inhibition

Indexed keywords

DOVITINIB; MESSENGER RNA; NERVE CELL ADHESION MOLECULE; UVOMORULIN; VIMENTIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CANCER; CANCER CELL CULTURE; CELL CONTACT; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CLONOGENIC ASSAY; COLONY FORMATION; CONTROLLED STUDY; DOSE RESPONSE; ENZYME INHIBITION; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; IC 50; PREDICTOR VARIABLE; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANTIGENS, CD; ANTINEOPLASTIC AGENTS; BENZIMIDAZOLES; CADHERINS; CELL LINE, TUMOR; CELL SURVIVAL; DRUG SCREENING ASSAYS, ANTITUMOR; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION; HUMANS; INHIBITORY CONCENTRATION 50; QUINOLONES; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; SIGNAL TRANSDUCTION; URINARY BLADDER NEOPLASMS; VIMENTIN;

EID: 84889847173     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-589     Document Type: Article

References (30)

1. Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 2010, 10(2):116-129. 10.1038/nrc2780, 20094046.
2. Sibley K, Stern P, Knowles MA. Frequency of fibroblast growth factor receptor 3 mutations in sporadic tumours. Oncogene 2001, 20(32):4416-4418. 10.1038/sj.onc.1204543, 11466624.
3. Tomlinson DC, Baldo O, Harnden P, Knowles MA. FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer. J Pathol 2007, 213(1):91-98. 10.1002/path.2207, 2443273, 17668422.
4. Tomlinson DC, Hurst CD, Knowles MA. Knockdown by shRNA identifies S249C mutant FGFR3 as a potential therapeutic target in bladder cancer. Oncogene 2007, 26(40):5889-5899. 10.1038/sj.onc.1210399, 2443272, 17384684.
5. Diez de Medina SG, Chopin D, el Marjou A, Delouvee A, LaRochelle WJ, Hoznek A, Abbou C, Aaronson SA, Thiery JP, Radvanyi F. Decreased expression of keratinocyte growth factor receptor in a subset of human transitional cell bladder carcinomas. Oncogene 1997, 14(3):323-330. 10.1038/sj.onc.1200830, 9018118.
6. Tomlinson DC, Lamont FR, Shnyder SD, Knowles MA. Fibroblast growth factor receptor 1 promotes proliferation and survival via activation of the mitogen-activated protein kinase pathway in bladder cancer. Cancer Res 2009, 69(11):4613-4620. 10.1158/0008-5472.CAN-08-2816, 2737316, 19458078.
7. Cheng T, Roth B, Choi W, Black PC, Dinney C, McConkey DJ. Fibroblast growth factor receptors-1 and -3 play distinct roles in the regulation of bladder cancer growth and metastasis: implications for therapeutic targeting. PLoS One 2013, 8(2):e57284. 10.1371/journal.pone.0057284, 3582560, 23468956.
8. Homsi J, Daud AI. Spectrum of activity and mechanism of action of VEGF/PDGF inhibitors. Cancer Control 2007, 14(3):285-294.
9. Folkman J. Angiogenesis: an organizing principle for drug discovery?. Nat Rev Drug Discov 2007, 6(4):273-286. 10.1038/nrd2115, 17396134.
10. Lamont FR, Tomlinson DC, Cooper PA, Shnyder SD, Chester JD, Knowles MA. Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo. Br J Cancer 2011, 104(1):75-82. 10.1038/sj.bjc.6606016, 3039817, 21119661.
11. Lee SH, Lopes de Menezes D, Vora J, Harris A, Ye H, Nordahl L, Garrett E, Samara E, Aukerman SL, Gelb AB, et al. In vivo target modulation and biological activity of CHIR-258, a multitargeted growth factor receptor kinase inhibitor, in colon cancer models. Clin Cancer Res 2005, 11(10):3633-3641. 10.1158/1078-0432.CCR-04-2129, 15897558.
12. Yao D, Dai C, Peng S. Mechanism of the mesenchymal-epithelial transition and its relationship with metastatic tumor formation. Mol Cancer Res 2011, 9(12):1608-1620. 10.1158/1541-7786.MCR-10-0568, 21840933.
13. McConkey DJ, Choi W, Marquis L, Martin F, Williams MB, Shah J, Svatek R, Das A, Adam L, Kamat A, et al. Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer. Cancer Metastasis Rev 2009, 28(3-4):335-344.
14. Bryan RT, Tselepis C. Cadherin switching and bladder cancer. J Urol 2010, 184(2):423-431. 10.1016/j.juro.2010.04.016, 20620393.
15. Jeanes A, Gottardi CJ, Yap AS. Cadherins and cancer: how does cadherin dysfunction promote tumor progression?. Oncogene 2008, 27(55):6920-6929. 10.1038/onc.2008.343, 2745643, 19029934.
16. Jager T, Becker M, Eisenhardt A, Tilki D, Totsch M, Schmid KW, Romics I, Rubben H, Ergun S, Szarvas T. The prognostic value of cadherin switch in bladder cancer. Oncol Rep 2010, 23(4):1125-1132.
17. Thiery JP, Sleeman JP. Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol 2006, 7(2):131-142. 10.1038/nrm1835, 16493418.
18. Fuxe J, Vincent T, Garcia de Herreros A. Transcriptional crosstalk between TGF-beta and stem cell pathways in tumor cell invasion: role of EMT promoting Smad complexes. Cell Cycle 2010, 9(12):2363-2374. 10.4161/cc.9.12.12050, 20519943.
19. Blaveri E, Simko JP, Korkola JE, Brewer JL, Baehner F, Mehta K, Devries S, Koppie T, Pejavar S, Carroll P, et al. Bladder cancer outcome and subtype classification by gene expression. Clin Cancer Res 2005, 11(11):4044-4055. 10.1158/1078-0432.CCR-04-2409, 15930339.
20. Dinney CP, McConkey DJ, Millikan RE, Wu X, Bar-Eli M, Adam L, Kamat AM, Siefker-Radtke AO, Tuziak T, Sabichi AL, et al. Focus on bladder cancer. Cancer Cell 2004, 6(2):111-116. 10.1016/j.ccr.2004.08.002, 15324694.
21. Sanchez-Carbayo M, Socci ND, Lozano J, Saint F, Cordon-Cardo C. Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J Clin Oncol 2006, 24(5):778-789. 10.1200/JCO.2005.03.2375, 16432078.
22. Black PC, Brown GA, Inamoto T, Shrader M, Arora A, Siefker-Radtke AO, Adam L, Theodorescu D, Wu X, Munsell MF, et al. Sensitivity to epidermal growth factor receptor inhibitor requires E-cadherin expression in urothelial carcinoma cells. Clin Cancer Res 2008, 14(5):1478-1486. 10.1158/1078-0432.CCR-07-1593, 18316572.
23. Shrader M, Pino MS, Brown G, Black P, Adam L, Bar-Eli M, Dinney CP, McConkey DJ. Molecular correlates of gefitinib responsiveness in human bladder cancer cells. Mol Cancer Ther 2007, 6(1):277-285. 10.1158/1535-7163.MCT-06-0513, 17237287.
24. Grunert S, Jechlinger M, Beug H. Diverse cellular and molecular mechanisms contribute to epithelial plasticity and metastasis. Nat Rev Mol Cell Biol 2003, 4(8):657-665. 10.1038/nrm1175, 12923528.
25. Mitra AP, Cote RJ. Molecular pathogenesis and diagnostics of bladder cancer. Annu Rev Pathol 2009, 4:251-285. 10.1146/annurev.pathol.4.110807.092230, 18840072.
26. Mandeville JA, Silva Neto B, Vanni AJ, Smith GL, Rieger-Christ KM, Zeheb R, Loda M, Libertino JA, Summerhayes IC. P-cadherin as a prognostic indicator and a modulator of migratory behaviour in bladder carcinoma cells. BJU Int 2008, 102(11):1707-1714. 10.1111/j.1464-410X.2008.08115.x, 18990147.
27. Bryan RT, Atherfold PA, Yeo Y, Jones LJ, Harrison RF, Wallace DM, Jankowski JA. Cadherin switching dictates the biology of transitional cell carcinoma of the bladder: ex vivo and in vitro studies. J Pathol 2008, 215(2):184-194. 10.1002/path.2346, 18393367.
28. Rieger-Christ KM, Cain JW, Braasch JW, Dugan JM, Silverman ML, Bouyounes B, Libertino JA, Summerhayes IC. Expression of classic cadherins type I in urothelial neoplastic progression. Hum Pathol 2001, 32(1):18-23. 10.1053/hupa.2001.21140, 11172290.
29. Witsch E, Sela M, Yarden Y. Roles for growth factors in cancer progression. Physiology (Bethesda) 2010, 25(2):85-101. 10.1152/physiol.00045.2009, 3062054, 20430953.
30. Hasinoff BB, Wu X, Nitiss JL, Kanagasabai R, Yalowich JC. The anticancer multi-kinase inhibitor dovitinib also targets topoisomerase I and topoisomerase II. Biochem Pharmacol 2012, 84(12):1617-1626. 10.1016/j.bcp.2012.09.023, 3501595, 23041231.